The vasopressin V1b receptor as a therapeutic target in stress-related disorders
Abstract
The complexity of the stress response would appear to provide multiple opportunities for intervention, but treatment strategies are often centered on the improvement of symptoms rather than attempting to "treat" the stress response. However, recent efforts have begun to focus on the development of pharmacological agents that can attenuate the stress response itself, rather than the symptoms associated with stress. Although CRF, which is the main regulator of the stress system, is the focus of current interest, there is an accumulating body of evidence suggesting that the vasopressinergic system may play an equal role in the regulation of the stress response, and that V(1b) receptor antagonists may be of potential therapeutic benefit. The availability of SSR149415, the first selective antagonist for the V(1b) receptor has allowed us to evaluate this hypothesis. SSR149415 is able to attenuate some but not all stress-related behaviors in rodents. While the antidepressant-like activity of the compound was comparable to that of reference antidepressants, the overall profile displayed in anxiety tests was different from that of classical anxiolytics, such as benzodiazepines. The latter were active in a wide range of anxiety models, whereas the V(1b) receptor antagonist showed clear-cut effects only in particularly stressful situations. It is important to note that SSR149415 is devoid of central depressant effects, even at high doses, and does not affect cognitive processes, suggesting a large therapeutic window. Altogether, these findings suggest that V(1b) receptor antagonists might be useful as a treatment for major depression and stress disorders that result from traumatic events.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Growing evidence suggests an important role for V1bR in behavioral and neuroendocrine modulation.
“Growing evidence suggests an important role for V1bR in behavioral and neuroendocrine modulation (Griebel et al., 2003; Smith et al., 2016; Stevenson and Caldwell, 2012).”
From Neuropeptide diversity and the regulation of social behavior in New World primates (2016) · cites this paper as Griebel et al., 2003
Cited by
Sorted by citations
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 549 · see citing works
Copeptin: clinical use of a new biomarker
Morgenthaler, N. G., Struck, J., Jochberger, S., & Dünser, M. W. (2008) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2007.11.001 · Cited by 412 · see citing works
Vasopressin V1a and V1b Receptors: From Molecules to Physiological Systems
Koshimizu, T., Nakamura, K., Egashira, N., Hiroyama, M., Nonoguchi, H., & Tanoue, A. (2012) · Physiological Reviews · doi:10.1152/physrev.00035.2011 · Cited by 413 · see citing works
Innovative approaches for the development of antidepressant drugs: Current and future strategies
Schechter, L. E., Ring, R. H., Beyer, C. E., Hughes, Z. A., Khawaja, X. Z., Malberg, J. E., & Rosenzweig-Lipson, S. J. (2005) · NeuroRx · doi:10.1602/neurorx.2.4.590 · Cited by 229 · see citing works
Behavioral effects of neuropeptides in rodent models of depression and anxiety
Rotzinger, S., Lovejoy, D. A., & Tan, L. A. (2010) · Peptides · doi:10.1016/j.peptides.2009.12.015 · Cited by 211 · see citing works
Pagani, J. H., Zhao, M., Cui, Z., Williams Avram, S. K., Caruana, D. A., Dudek, S. M., & Young, W. S. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.47 · Cited by 204 · see citing works
Copeptin: A Biomarker of Cardiovascular and Renal Function
Morgenthaler, N. G. (2010) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2010.00177.x · Cited by 179 · see citing works
Merali, Z., Kent, P., Du, L., Hrdina, P. D., Palkovits, M., Faludi, G., Poulter, M. O., Bédard, T., & Anisman, H. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.08.008 · Cited by 155 · see citing works
Innovative Approaches for the Treatment of Depression: Targeting the HPA Axis
THOMSON, F. J., & Craighead, M. W. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9518-3 · Cited by 155 · see citing works
The Central Vasopressinergic System: Examining the Opportunities for Psychiatric Drug Development
Ring, R. H. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053382241 · Cited by 141 · see citing works
Wersinger, S. R., Kelliher, K. R., Zufall, F., Lolait, S. J., O’Carroll, A., & Young, W. S. (2004) · Hormones and Behavior · doi:10.1016/j.yhbeh.2004.07.004 · Cited by 132 · see citing works
Wersinger, S. R., Caldwell, H. K., Christiansen, M., & Young, W. S. (2006) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2006.00294.x · Cited by 130 · see citing works
Exploring the role of neuropeptides in depression and anxiety
Rana, T., Behl, T., Sehgal, A., Singh, S., Sharma, N., Abdeen, A., Ibrahim, S. F., Mani, V., Iqbal, M. S., Bhatia, S., et al. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110478 · Cited by 126 · see citing works
Stemmelin, J., Lukovic, L., Salome, N., & Griebel, G. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300562 · Cited by 112 · see citing works
Self-citationKeck, M. E., Kern, N., Erhardt, A., Unschuld, P. G., Ising, M., Salyakina, D., Müller, M. B., Knorr, C. C., Lieb, R., Hohoff, C., et al. (2008) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30750 · Cited by 113 · see citing works
Gal, C. S., Wagnon, J., Tonnerre, B., Roux, R., Garcia, G., Griebel, G., & Aulombard, A. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2005.tb00035.x · Cited by 110 · see citing works
Self-citationAVP V selective antagonist SSR149415 blocks aggressive behaviors in hamsters
Blanchard, R. J., Griebel, G., Farrokhi, C. B., Markham, C. M., YANG, M., & Blanchard, D. C. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.10.024 · Cited by 94 · see citing works
Self-citationCorticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety
Keck, M. E. (2006) · Amino Acids · doi:10.1007/s00726-006-0333-y · Cited by 92 · see citing works
Salomé, N., Stemmelin, J., Cohen, C., & Griebel, G. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0424-1 · Cited by 89 · see citing works
Self-citationIs AD a Stress-Related Disorder? Focus on the HPA Axis and Its Promising Therapeutic Targets
Canet, G., Hernandez, C., Zussy, C., Chevallier, N., Desrumaux, C. M., & Givalois, L. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00269 · Cited by 89 · see citing works
Griebel, G., Stemmelin, J., Gal, C. S., & Soubrié, P. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053764797 · Cited by 84 · see citing works
Self-citationThe pharmacological properties of antidepressants
Racagni, G., & Popoli, M. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283311acd · Cited by 83 · see citing works
Malemud, C. J., & Miller, A. H. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.2.171 · Cited by 77 · see citing works
Grigoriadis, D. E. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.4.651 · Cited by 75 · see citing works
Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior
Bleickardt, C. J., Mullins, D. E., MacSweeney, C. P., Werner, B. J., Pond, A. J., Guzzi, M. F., Martin, F. D. C., Varty, G. B., & Hodgson, R. A. (2009) · Psychopharmacology · doi:10.1007/s00213-008-1354-x · Cited by 71 · see citing works
Neuropeptide diversity and the regulation of social behavior in New World primates
French, J. A., Taylor, J. H., Mustoe, A. C., & Cavanaugh, J. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2016.03.004 · Cited by 66 · see citing works
SALOME, N., Stemmelin, J., Cohen, C., et al. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.03.013 · Cited by 66 · see citing works
Self-citationOptogenetics to study the circuits of fear- and depression-like behaviors: A critical analysis
Belzung, C., Turiault, M., & Griebel, G. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.04.002 · Cited by 63 · see citing works
Self-citationGriffante, C., Green, A., Curcuruto, O., Haslam, C. P., Dickinson, B. A., & Arban, R. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706383 · Cited by 60 · see citing works
Genetic, epigenetic and environmental impact on sex differences in social behavior
Shepard, K. N., Michopoulos, V., Toufexis, D. J., & Wilson, M. E. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.02.016 · Cited by 57 · see citing works
Iijima, M., Yoshimizu, T., Shimazaki, T., Tokugawa, K., Fukumoto, K., Kurosu, S., Kuwada, T., Sekiguchi, Y., & Chaki, S. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12699 · Cited by 55 · see citing works
Wang, L., Martı́nez, V., Larauche, M. H., & Taché, Y. (2008) · Brain Research · doi:10.1016/j.brainres.2008.09.094 · Cited by 52 · see citing works
The Role of Serotonin, Vasopressin, and Serotonin/Vasopressin Interactions in Aggressive Behavior
Morrison, T. R., & Melloni, R. H. (2014) · Current topics in behavioral neurosciences · doi:10.1007/7854_2014_283 · Cited by 51 · see citing works
Vasopressin: A Review of Therapeutic Applications
Holt, N. F., & Haspel, K. L. (2009) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2009.09.006 · Cited by 41 · see citing works
Lippi, G., Plebani, M., Somma, S. D., Monzani, V., Marco Tubaro, U., Volpe, M., Moscatelli, P., Vernocchi, A., Cavazza, M., Galvani, M., et al. (2012) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2011-0845 · Cited by 41 · see citing works
Jurkevich, A., Berghman, L. R., Cornett, L. E., & Kuenzel, W. J. (2005) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2005.02.017 · Cited by 41 · see citing works
Social Context, Stress, Neuropsychiatric Disorders, and the Vasopressin 1b Receptor
Caldwell, H. K., Aulino, E. A., Rodriguez, K. M., Witchey, S. K., & Yaw, A. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00567 · Cited by 39 · see citing works
Dobruch, J. T., Cudnoch‐Jędrzejewska, A., & Szczepanska‐Sadowska, E. K. (2005) · Stress · doi:10.1080/10253890500456287 · Cited by 40 · see citing works
Cid-Jofré, V., Moreno, M., Reyes-Parada, M. I., & Renard, G. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112077 · Cited by 39 · see citing works
The acute intoxicating effects of ethanol are not dependent on the vasopressin 1a or 1b receptors
Caldwell, H. K., Stewart, J., Wiedholz, L. M., Millstein, R. A., Iacangelo, A. L., Holmes, A., Young, W. S., & Wersinger, S. R. (2006) · Neuropeptides · doi:10.1016/j.npep.2006.08.001 · Cited by 39 · see citing works
Neuropeptide and Sigma Receptors as Novel Therapeutic Targets for the Pharmacotherapy of Depression
Paschos, K. A., Veletza, S. V., & Chatzaki, Ε. (2009) · CNS Drugs · doi:10.2165/11310830-000000000-00000 · Cited by 36 · see citing works
Savas, S., Hyde, A. J., Stuckless, S. N., Parfrey, P. S., Younghusband, H. B., & Green, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038953 · Cited by 33 · see citing works
Bradesi, S., Martı́nez, V., Lao, L., Larsson, H., & Mayer, E. A. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90557.2008 · Cited by 33 · see citing works
Roles of arginine vasotocin receptors in the brain and pituitary of submammalian vertebrates
(2013) · International Review of Cell and Molecular Biology · doi:10.1016/b978-0-12-407696-9.00004-x · Cited by 30 · see citing works
Breuer, M. E., van Gaalen, M. M., Wernet, W., Claessens, S. E. F., Oosting, R. S., Behl, B., Korte, S. M., Schoemaker, H., Gross, G., Olivier, B., et al. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0336-1 · Cited by 32 · see citing works
Pharmacological evaluation of the stress-induced social avoidance model of anxiety
Leveleki, C., Sziray, N., Lévay, G. I., Barsvári, B., Soproni, K., Mikics, É., & Haller, J. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2005.11.015 · Cited by 30 · see citing works
Cudnoch‐Jędrzejewska, A., Dobruch, J. T., Puchalska, L., & Szczepanska‐Sadowska, E. K. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.01.010 · Cited by 26 · see citing works
Synthesis of [11C]SSR149415 and preliminary imaging studies using positron emission tomography
Schönberger, M., Leggett, C. S., Kim, S. W., & Hooker, J. M. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.108 · Cited by 24 · see citing works
Balázsfi, D., Pintér, O., Klausz, B., Kovács, K., Fodor, A., Török, B., Engelmann, M., & Zelena, D. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.09.011 · Cited by 21 · see citing works
Vasopressinergic control of stress-related behavior: studies in Brattleboro rats
Csikota, P., Fodor, A., Balázsfi, D., Pintér, O., Mizukami, H., Weger, S., Heilbronn, R., Engelmann, M., & Zelena, D. (2016) · Stress · doi:10.1080/10253890.2016.1183117 · Cited by 21 · see citing works
Chaki, S., Yamaguchi, J.-I., Yamada, H., Thomsen, W. J., Tran, T.-A., Semple, G., & Sekiguchi, Y. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2005.tb00052.x · Cited by 20 · see citing works
Effects of Cocaine on Maternal Behavior and Neurochemistry
Nephew, B. C., & Febo, M. (2012) · Current Neuropharmacology · doi:10.2174/157015912799362760 · Cited by 18 · see citing works
A complex selection signature at the human AVPR1B gene
Cagliani, R., Fumagalli, M., Pozzoli, U., Riva, S., Cereda, M., Comi, G. P., Pattini, L., Bresolin, N., & Sironi, M. (2009) · BMC Evolutionary Biology · doi:10.1186/1471-2148-9-123 · Cited by 17 · see citing works
Emerging treatments for major depression
Norman, T. R., & Burrows, G. D. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.2.203 · Cited by 17 · see citing works
Papp, A., Jurányi, Z., Nagymajtényi, L., et al. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.06.030 · Cited by 16 · see citing works
Prospects for the Treatment of Depression
Norman, T. R. (2006) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2006.01814.x · Cited by 16 · see citing works
Kashkouli, M., Sadatmahalleh, S. J., Ziaei, S., Kazemnejad, A., Saber, A., Darvishnia, H., & Azarbayjani, K. (2023) · Scientific Reports · doi:10.1038/s41598-022-27223-6 · Cited by 13 · see citing works
Claustre, Y., Rouquier, L., Desvignes, C., Leonetti, M., Montégut, J., Aubin, N., Allouard, N., Bougault, I., Oury-Donat, F., & Steinberg, R. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.05.006 · Cited by 13 · see citing works
Self-citationPharmacological characterization of RWJ-676070, a dual vasopressin V1A/V2 receptor antagonist
Gunnet, J. W., Wines, P. G., Xiang, M. A., et al. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.010 · Cited by 13 · see citing works
Cudnoch‐Jędrzejewska, A., Puchalska, L., Szczepanska‐Sadowska, E. K., Wsół, A., Kowalewski, S., & Czarzasta, K. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.06.011 · Cited by 12 · see citing works
Chapter 4.1 Peptide receptor ligands to treat anxiety disorders
Steckler, T. (2008) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(07)00010-0 · Cited by 10 · see citing works
Purushotham, S. S., Reddy, N. M. N., D’Souza, M. N., Choudhury, N. R., Ganguly, A., Gopalakrishna, N., Muddashetty, R. S., & Clement, J. P. (2022) · Experimental Brain Research · doi:10.1007/s00221-022-06448-x · Cited by 8 · see citing works
V1b Receptors: New Probes for Therapy
Arban, R. (2007) · Endocrinology · doi:10.1210/en.2007-0735 · Cited by 8 · see citing works
Wang, B., Zhou, J., Zhuang, Y., Wang, L., Pu, J., Huang, Y., Xia, F., & Lv, J. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26040 · Cited by 6 · see citing works
Belyakova, A. S., Sinjushin, A. A., Voskresenskaya, O. G., et al. (2015) · Neurochemical Journal · doi:10.1134/s1819712415030034 · Cited by 5 · see citing works
Prospects for the treatment of depression
Norman, T. R. (2006) · Australian & New Zealand Journal of Psychiatry · doi:10.1111/j.1440-1614.2006.01814.x · Cited by 2 · see citing works
Endocrine and Metabolic Agents
Furman, B. L. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse024 · Cited by 1 · see citing works
Choleris, E., Pfaff, D. W., & Kavaliers, M. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139017855.021 · Cited by 1 · see citing works
Copeptina: utilidade na prática clínica
Rodrigues, P. P., Castedo, J. L., Guimarães, J. T., & Carvalho, D. M. (2012) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.1016/s1646-3439(12)70006-8
Angsterkrankungen: Tiermodelle und Humangenetik
Keck, M. E., & Thöringer, C. K. (2005) · psychoneuro · doi:10.1055/s-2005-866813
Stedenfeld, K. A. (2011) · D-Scholarship@Pitt (University of Pittsburgh)
Talati, A., & Weissman, M. M. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139025997.010
Martinetz, S. (2014) · University of Regensburg Publication Server (University of Regensburg) · doi:10.5283/epub.30767
Rôle central des glucocorticoïdes et de leurs récepteurs dans l’étiologie de la Maladie d’Alzheimer
Canet, G. (2020) · theses.fr (ABES) · doi:10.70675/c46cedbczd8bbz4a8eza301z82de5785048c
- Authors
- Griebel, G., Simiand, J., Stemmelin, J., Gal, C., & Steinberg, R.
- Affiliations
- Sanofi (France) (FR)
- ORCID
- Griebel, Guy
- Venue
- Current Drug Target -CNS & Neurological Disorders
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-06-01
- Volume
- 2
- Issue
- 3
- Pages
- 191-200
- ISSN
- 1568-007X (ISSN-L)
- OpenAlex
- W1986878594
- Cited by
- 74
- References
- 0
- Citations by year
- 2023: 1 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2017: 2 · 2016: 2 · 2015: 1 · 2014: 7 · 2013: 2 · 2012: 6
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS & Neurological Disorders - Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Social Sciences › Psychology › Social Psychology › Neuroendocrine regulation and behavior
- Keywords
- vasopressin V1b receptor, stress response, stress-related disorders, major depressive disorder, traumatic stress, corticotropin-releasing factor, antidepressant-like effects, anxiety, benzodiazepines, receptor antagonists
- MeSH terms
- Animals, Antidepressive Agents, Anxiety Disorders, Behavior, Animal, Disease Models, Animal, Drug Evaluation, Preclinical, Forecasting, Gerbillinae, Humans, Indoles, Pyrrolidines, Stress, Psychological, Anti-Anxiety Agents, Receptors, Vasopressin, Mice, Rats, Antidiuretic Hormone Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
